The ZENITH20 study (NCT03318939) was a multicenter, multi-cohort phase II clinical trial in which cohort 1 included poziotinib 16 mg QD for NSCLC patients with EGFR ex20ins and prior platinum-based chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.